Format

Send to

Choose Destination
Vaccine. 2004 Dec 6;22 Suppl 1:S39-43.

A humanized monoclonal antibody targeting Staphylococcus aureus.

Author information

1
Inhibitex Inc., 1165 Westside Parkway, Suite 400, Alpharetta, GA 30004, USA. jpatti@inhibitex.com

Abstract

This current presentation describes the in vitro and in vivo characterization of Aurexis (tefibazumab), a humanized monoclonal antibody that exhibits a high affinity and specificity and for the Staphylococcus aureus MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein ClfA. Aurexis inhibited ClfA binding to human fibrinogen, and enhanced the opsonophagocytic uptake of ClfA-coated beads. Preclinical in vivo testing revealed that a single administration of Aurexis significantly protected against an IV challenge with a methicillin resistant S. aureus (MRSA) strain in murine septicemia and rabbit infective endocarditis (IE) models. Safety and pharmacokinetic data from a 19-patient phase I study support continued evaluation of Aurexis in phase II studies.

PMID:
15576200
DOI:
10.1016/j.vaccine.2004.08.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center